BlackRock’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-210,981
| Closed | -$131K | – | 5170 |
|
|
2018
Q4 | $131K | Sell |
210,981
-995
| -0.5% | -$1.03K | ﹤0.01% | 4305 |
|
|
2018
Q3 | $275K | Buy |
211,976
+3,694
| +2% | +$5.74K | ﹤0.01% | 4261 |
|
|
2018
Q2 | $281K | Sell |
208,282
-1,101,220
| -84% | -$1.69M | ﹤0.01% | 4240 |
|
|
2018
Q1 | $1.9M | Buy |
1,309,502
+6,385
| +0.5% | +$13.3K | ﹤0.01% | 3688 |
|
|
2017
Q4 | $2.93M | Buy |
1,303,117
+14,908
| +1% | +$37.7K | ﹤0.01% | 3595 |
|
|
2017
Q3 | $4.38M | Buy |
1,288,209
+51,882
| +4% | +$175K | ﹤0.01% | 3502 |
|
|
2017
Q2 | $4.39M | Buy |
1,236,327
+114,034
| +10% | +$376K | ﹤0.01% | 3503 |
|
|
2017
Q1 | $3.82M | Buy |
1,122,293
+1,121,035
| +89,112% | +$4.36M | ﹤0.01% | 3467 |
|
|
2016
Q4 | $6K | Hold |
1,258
| – | – | ﹤0.01% | 3514 |
|
|
2016
Q3 | $5K | Hold |
1,258
| – | – | ﹤0.01% | 3521 |
|
|
2016
Q2 | $3K | Buy |
1,258
+1,022
| +433% | +$3.69K | ﹤0.01% | 3621 |
|
|
2016
Q1 | $1K | Buy |
+236
| New | +$913 | ﹤0.01% | 3627 |
|
BlackRock's AST Position: Q1 2019 in Review
BlackRock sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 210,981 shares — an estimated $131K sold.
BlackRock first reported a position in AST in Q1 2016 and held it in 12 quarters. The position peaked at $4.39M in Q2 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- BlackRock reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- BlackRock sold 210,981 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $131K.
- BlackRock first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2016 and held it in 12 quarters.
- BlackRock's Asterias Biotherapeutics Inc. Series A position peaked at $4.39M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on BlackRock's 13F filing for Q1 2019, filed 9 May 2019.